| NCT03322865 |
Obinutuzumab in Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03322865 |
Recruiting |
University of Ulm |
2020-10-02 |
| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
https://ClinicalTrials.gov/show/NCT03314974 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2025-01-10 |
| NCT03277729 |
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT03277729 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-11-16 |
| NCT03276468 |
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas |
https://ClinicalTrials.gov/show/NCT03276468 |
Recruiting |
The Lymphoma Academic Research Organisation |
2019-09-19 |
| NCT03162536 |
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03162536 |
Recruiting |
ArQule |
2021-12-31 |
| NCT03144674 |
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) |
https://ClinicalTrials.gov/show/NCT03144674 |
Active, not recruiting |
Incyte Corporation |
2021-01-31 |
| NCT03105336 |
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03105336 |
Recruiting |
Gilead Sciences |
2022-02-28 |
| NCT03093831 |
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03093831 |
Recruiting |
National Cancer Centre, Singapore |
2020-01-31 |
| NCT03078855 |
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03078855 |
Recruiting |
University of Rochester |
2023-09-30 |
| NCT03037645 |
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers |
https://ClinicalTrials.gov/show/NCT03037645 |
Recruiting |
Sunesis Pharmaceuticals |
2020-12-31 |
| NCT03031483 |
Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03031483 |
Active, not recruiting |
International Extranodal Lymphoma Study Group (IELSG) |
2021-02-28 |
| NCT02914938 |
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02914938 |
Recruiting |
MEI Pharma, Inc. |
2021-09-30 |
| NCT02853370 |
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT02853370 |
Active, not recruiting |
International Extranodal Lymphoma Study Group (IELSG) |
2020-09-30 |
| NCT02722668 |
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
https://ClinicalTrials.gov/show/NCT02722668 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2028-05-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02927964 |
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma |
https://ClinicalTrials.gov/show/NCT02927964 |
Recruiting |
Stanford University |
2021-11-30 |
| NCT02568553 |
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02568553 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02532257 |
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT02532257 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-01 |
| NCT02494700 |
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02494700 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT02433795 |
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) |
https://ClinicalTrials.gov/show/NCT02433795 |
Completed |
Seoul National University Hospital |
2019-10-31 |
| NCT02339922 |
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02339922 |
Active, not recruiting |
University of Washington |
2025-01-06 |
| NCT02332980 |
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT02332980 |
Recruiting |
Mayo Clinic |
2021-01-05 |
| NCT02257242 |
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02257242 |
Recruiting |
Brown University |
2020-12-31 |
| NCT02254772 |
A Phase I/II Study of Intratumoral Injection of SD-101 |
https://ClinicalTrials.gov/show/NCT02254772 |
Completed |
Stanford University |
2016-11-10 |
| NCT02213913 |
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02213913 |
Recruiting |
University of Chicago |
2020-07-29 |
| NCT01306643 |
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma |
https://ClinicalTrials.gov/show/NCT01306643 |
Completed |
Gilead Sciences |
2015-08-31 |
| NCT01282424 |
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT01282424 |
Completed |
Gilead Sciences |
2018-05-02 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT02049541 |
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02049541 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2018-09-12 |
| NCT03479268 |
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03479268 |
Recruiting |
City of Hope Medical Center |
2022-04-01 |
| NCT01995669 |
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01995669 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-05-31 |
| NCT01980628 |
Study of the Bruton’s Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT01980628 |
Completed |
Pharmacyclics LLC. |
2016-07-31 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01820910 |
Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment |
https://ClinicalTrials.gov/show/NCT01820910 |
Active, not recruiting |
International Extranodal Lymphoma Study Group (IELSG) |
2016-05-31 |
| NCT01815749 |
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01815749 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-31 |
| NCT01808599 |
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma |
https://ClinicalTrials.gov/show/NCT01808599 |
Active, not recruiting |
International Extranodal Lymphoma Study Group (IELSG) |
2016-03-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01701232 |
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01701232 |
Completed |
Biocad |
2017-01-31 |
| NCT01682044 |
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT01682044 |
Completed |
Roswell Park Cancer Institute |
2013-11-22 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01583699 |
Endomicroscopy and Gastric MALT-lymphoma |
https://ClinicalTrials.gov/show/NCT01583699 |
Completed |
Medical University of Vienna |
2014-03-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01479842 |
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01479842 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2014-03-31 |
| NCT01460134 |
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01460134 |
Completed |
Celldex Therapeutics |
2015-12-31 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01427114 |
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) |
https://ClinicalTrials.gov/show/NCT01427114 |
Active, not recruiting |
Konkuk University Medical Center |
2014-08-01 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04433156 |
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT04433156 |
Recruiting |
Henan Cancer Hospital |
2022-04-22 |
| NCT04323956 |
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04323956 |
Recruiting |
Mayo Clinic |
2026-05-15 |
| NCT04212013 |
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT04212013 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2024-06-30 |
| NCT04205409 |
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04205409 |
Recruiting |
University of Washington |
2022-08-01 |
| NCT04097067 |
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma |
https://ClinicalTrials.gov/show/NCT04097067 |
Recruiting |
University Hospital Muenster |
2021-08-31 |
| NCT04082936 |
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04082936 |
Recruiting |
IGM Biosciences, Inc. |
2021-09-30 |
| NCT04014205 |
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT04014205 |
Recruiting |
Beijing InnoCare Pharma Tech Co., Ltd. |
2020-08-17 |
| NCT03999697 |
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT03999697 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2020-12-01 |
| NCT03919175 |
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03919175 |
Recruiting |
Massachusetts General Hospital |
2022-11-30 |
| NCT03846427 |
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT03846427 |
Active, not recruiting |
BeiGene |
2021-04-01 |
| NCT03797456 |
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) |
https://ClinicalTrials.gov/show/NCT03797456 |
Recruiting |
Beijing InnoCare Pharma Tech Co., Ltd. |
2021-02-28 |
| NCT03740529 |
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL |
https://ClinicalTrials.gov/show/NCT03740529 |
Recruiting |
Loxo Oncology, Inc. |
2020-10-31 |
| NCT03697512 |
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas |
https://ClinicalTrials.gov/show/NCT03697512 |
Recruiting |
International Extranodal Lymphoma Study Group (IELSG) |
2024-06-15 |
| NCT03680586 |
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma |
https://ClinicalTrials.gov/show/NCT03680586 |
Recruiting |
M.D. Anderson Cancer Center |
2021-05-08 |
| NCT03583424 |
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03583424 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-12-31 |
| NCT03498612 |
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases |
https://ClinicalTrials.gov/show/NCT03498612 |
Recruiting |
University of Washington |
2022-09-16 |
| NCT03474744 |
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03474744 |
Recruiting |
University of Ulm |
2028-06-01 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01239875 |
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01239875 |
Completed |
Mayo Clinic |
2015-11-24 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01213095 |
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL) |
https://ClinicalTrials.gov/show/NCT01213095 |
Completed |
Dong-A University Hospital |
2013-09-30 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01164267 |
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) |
https://ClinicalTrials.gov/show/NCT01164267 |
Completed |
International Extranodal Lymphoma Study Group (IELSG) |
2012-12-31 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01068392 |
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) |
https://ClinicalTrials.gov/show/NCT01068392 |
Completed |
Dong-A University Hospital |
2013-09-30 |
| NCT01015248 |
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma |
https://ClinicalTrials.gov/show/NCT01015248 |
Completed |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2013-12-31 |
| NCT00991211 |
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab |
https://ClinicalTrials.gov/show/NCT00991211 |
Completed |
University of Giessen |
2009-08-31 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00877214 |
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT00877214 |
Active, not recruiting |
University of Giessen |
2022-04-30 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT00801281 |
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. |
https://ClinicalTrials.gov/show/NCT00801281 |
Completed |
Polish Lymphoma Research Group |
2017-06-25 |
| NCT03520920 |
BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) |
https://ClinicalTrials.gov/show/NCT03520920 |
Active, not recruiting |
BeiGene |
2020-11-30 |
| NCT03147885 |
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03147885 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-06-30 |
| NCT04298879 |
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT04298879 |
Recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2021-07-31 |
| NCT00783367 |
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00783367 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2012-11-14 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00720135 |
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00720135 |
Completed |
City of Hope Medical Center |
2014-07-31 |
| NCT00711828 |
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00711828 |
Completed |
Mayo Clinic |
2013-11-30 |
| NCT00695786 |
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00695786 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-06-30 |
| NCT00656812 |
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma |
https://ClinicalTrials.gov/show/NCT00656812 |
Completed |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2011-09-30 |
| NCT00621452 |
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00621452 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-01-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00566332 |
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia |
https://ClinicalTrials.gov/show/NCT00566332 |
Completed |
French Study Group on Chronic Lymphoid Leukemia |
2009-09-30 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00453102 |
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma |
https://ClinicalTrials.gov/show/NCT00453102 |
Completed |
University of Miami |
2015-02-28 |
| NCT00438880 |
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00438880 |
Completed |
Mayo Clinic |
2010-10-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00373906 |
Velcade in MALT Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00373906 |
Completed |
Medical University of Vienna |
NA |
| NCT00373646 |
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00373646 |
Completed |
Medical University of Vienna |
2009-01-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00327132 |
Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome |
https://ClinicalTrials.gov/show/NCT00327132 |
Completed |
National Health Research Institutes, Taiwan |
2015-12-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00290472 |
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00290472 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00275080 |
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00275080 |
Completed |
National Cancer Institute (NCI) |
2009-11-30 |
| NCT00253630 |
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00253630 |
Completed |
National Cancer Institute (NCI) |
2016-05-31 |
| NCT00244855 |
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00244855 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-12-31 |
| NCT00210353 |
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma |
https://ClinicalTrials.gov/show/NCT00210353 |
Completed |
International Extranodal Lymphoma Study Group (IELSG) |
2015-04-30 |
| NCT00210327 |
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy |
https://ClinicalTrials.gov/show/NCT00210327 |
Completed |
International Extranodal Lymphoma Study Group (IELSG) |
2008-11-30 |
| NCT00201422 |
Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma |
https://ClinicalTrials.gov/show/NCT00201422 |
Completed |
National Health Research Institutes, Taiwan |
2004-01-31 |
| NCT00119392 |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00119392 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00118170 |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function |
https://ClinicalTrials.gov/show/NCT00118170 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00117156 |
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00117156 |
Completed |
Dana-Farber Cancer Institute |
2008-10-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00110071 |
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00110071 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00002682 |
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach |
https://ClinicalTrials.gov/show/NCT00002682 |
Completed |
M.D. Anderson Cancer Center |
2001-10-08 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00082784 |
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT00082784 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00068315 |
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00068315 |
Completed |
National Cancer Institute (NCI) |
2008-12-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00058305 |
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00058305 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00058227 |
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00058227 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00054639 |
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00054639 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00054483 |
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00054483 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00026182 |
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00026182 |
Completed |
National Cancer Institute (NCI) |
2005-02-28 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00017472 |
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00017472 |
Completed |
National Cancer Institute (NCI) |
2006-04-30 |
| NCT00017381 |
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00017381 |
Completed |
National Cancer Institute (NCI) |
2007-12-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00010192 |
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00010192 |
Completed |
National Cancer Institute (NCI) |
2003-01-31 |
| NCT00006473 |
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006473 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |